Article Text
PDFDTB select
No benefit from mirtazapine for treating agitation in dementia
Abstract
Review of: Banerjee S, High J, Stirling S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet 2021;398:1487–97.
- drug-related side effects and adverse reactions
- health care quality, access, and evaluation
Statistics from Altmetric.com
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.